GH Research PLC is a clinical-stage biopharmaceutical company. It dedicated to treat psychiatric and neurological disorders. The company's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. GH Research PLC is based in DUBLIN.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-38.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.66 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -19.20% |
| Return on Assets (Trailing 12 Months) | -18.40% |
| Current Ratio (Most Recent Fiscal Quarter) | 29.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 29.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.44 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.19 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.75 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.79 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 52.03M |
| Free Float | -- |
| Market Capitalization | $825.69M |
| Average Volume (Last 20 Days) | 0.16M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | -- |
| Percentage Held By Institutions (Latest 13F Reports) | 56.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |